Clinical trial demonstrates the therapeutic potential of RJx-01 in sarcopenia
Cutting-edge therapy shows meaningful improvements in muscle strength, function and fatigue resistance, offering hope for millions suffering from sarcopenia.
Positive results Phase 1b trial in sarcopenia
Primary and secondary endpoints have been met in this placebo-controlled study in disuse-induced muscle atrophy. RJx-01 was safe and well tolerated and the innovative formulation confirmed excellent pharmacokinetics.
Publication of animal data on RJx-01
Data published in JCI Insight show that RJx-01 significantly increases muscle mass, muscle strength and physical performance in sarcopenia mouse models.
Advisory Board endorses clinical Ph 2b strategy
Rejuvenate Biomed organized a Clinical Advisory Board meeting to discuss the clinical development of lead candidate RJx-01 in sarcopenia.
Groundbreaking clinical trial started
The first clinical trial with RJx-01 has started in disuse-induced muscle atrophy, marking Rejuvenate Biomed’s maturation to a clinical-stage company.